🔗 Share this article

Given that America continues making historic adjustments to its immunization recommendations, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 shots throughout the pandemic and has focused upon alleged fatalities after COVID-19 immunization in her short position at the FDA.

Planned Shifts to Pediatric Vaccine Schedule

Agency leaders planned to announce radical revisions to the pediatric immunization program recently, synchronizing the US with Denmark’s vaccine program, according to reports – a significant shift that would place the US out of step with much of the global community with little proof for benefit. The announcement has been delayed until the next year.

In place of Vinay Prasad, Høeg is set to address the audience at the gathering. She was recently named interim head of the FDA’s CDER, the fifth individual to run the center this year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad solidify control at the FDA – and it signals a renewed priority upon reevaluating already-approved vaccines at the FDA.

Høeg has often pushed for discontinuing specific childhood shot schedules in the US in order to be more in line with Denmark, a society with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

To date public appearances, she has persisted in emphasizing on vaccines – usually the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Questions Over Background

Dr. Høeg has no obvious background in pharmaceutical research, regulation or administrative roles, which has been customary for past directors of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and CBER since March.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a large organization. She lacks background in drug approvals.”

Previous heads of the center would “be deeply familiar with regulatory frameworks and the research of medication creation”, said a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that former directors who ran the center have had.”

The drug center has an immense range of responsibilities at the agency, she stated.

“Many people just zeroes in on the new drug program, but the generic drug division clears a multitude of generic drugs. There is also a biosimilars program, non-prescription drug unit and more, and each of these need to be looked after,” she noted. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a major management element to the position, which oversees over 5,000 personnel. “It’s a enormous administrative position, if you do it right,” the former official said.

Agency Reaction and Disputed Initiatives

When asked about concerns about Høeg’s qualifications and whether this appointment signifies greater collaboration among regulatory chiefs on vaccines, a representative responded that the “concerns are based on flawed presumptions”.

“Her resume is consistent with the responsibilities of her job,” the representative said, pointing to the period Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's recently launched priority voucher program, a controversial expedited therapy clearance system that reportedly troubled her predecessors. “By what process are these therapies being chosen for this voucher program? Who makes the calls?” Howard said. “There is a lot of lack of transparency happening at the agency right now.”

Broadly speaking, he stated, “the FDA seems to be moving towards laxer regulations of all drugs, except for immunizations.”

Public Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if troubling, track record, critics observe. She published a analysis using unconfirmed volunteer-provided data to assess the frequency of myocarditis after COVID-19 immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccinations are pose a greater threat than they are.

Among her “policy goals” for the current administration encompassed changing rules for recently developed shots and discontinuing “optional” vaccines, she remarked post-election on a online show. At the agency, Høeg has reportedly floated the idea of barring adolescent males from getting COVID-19 vaccines.

“She is an thorough dogmatist who begins with her beliefs and works backwards to retrofit the evidence in a extremely deceptive, untruthful fashion,” Dr. Howard stated.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with other contrarians, {like|